In timely and incisive analysis, our experts parse the latest development issues and events, providing practical solutions to new and emerging challenges.
These episodes are meant to capture the role of luck and privilege in my life, as an American during America’s near-hegemon years, and as a woman in a period of growing opportunities for women.
As the world awaits the results of COVID-19 vaccine clinical trials, we have interviewed sixteen vaccine experts from the vaccine industry, academic, and regulatory agencies. Their overall message: the time to prepare is now.
Our new paper aims to answer this question using mathematical modelling and expert interviews to: better understand the COVID-19 vaccine portfolio, and generate probabilistic estimates on timelines for approval and the manufacturing scale up.
We are developing a system of interconnected models which represent global manufacturing capability from the start of clinical trials to secondary vaccine manufacture; that is, time from first human trials to finished product ready to be shipped.